

Rule 4.2A

## Appendix 4E

### Preliminary Final Report

#### 1. Company details

Name of entity

**Pro Medicus Limited**

ABN or equivalent  
company reference

**25 006 194 752**

Financial year ended  
(‘current period’)

**30 June 2010**

Financial year ended  
(‘previous period’)

**30 June 2009**

#### 2. Results for announcement to the market

ASX Listing Rules Ref		2010 A\$'000
<b>2.1</b>	<b>Revenue</b>  % change up/(down) of revenue from ordinary activities from the previous corresponding period.	19,464  Up 24.6%
<b>2.2</b>	<b>Profit after tax attributable to members</b>  % change up/(down) of Profit/(Loss) from ordinary activities after tax attributable to members from the previous corresponding period.	3,920  Down 21.9%
<b>2.3</b>	<b>Net Profit for the period attributable to members</b>  % change up/(down) of Net Profit/(Loss) for the period attributable to members from the previous corresponding period.	3,920  Down 21.9%

<b>2.4</b>	<b>Dividends (distributions)</b>	Amount per security	Fully Franked amount per security
	Franked dividend amount per security		
	Final Dividend	2.0¢	2.0¢
	Interim dividend	-	-
<b>2.5</b>	<b>Record date for Final dividends</b>	16 September, 2010	
	Payment date for Final dividends	1 November, 2010	

<p><b>2.6</b></p>	<p>Australia</p> <p>The group's Australian revenue grew over the period by 12.7% with some decline in our service revenues due to market share erosion being offset through the release of the Visage range of products which created a total imaging centre solution and culminated in several strategically important new sales being secured. Other areas of the Australian operation remained steady despite the challenging environment over the past year. The group employs 25 people in Australia who undertake research and development of Pro Medicus products as well as sales and service/support functions.</p> <p>Promedicus.net, the company's e-health offering, continued to hold its strong market position recording revenue of \$2.05 million despite increasing competition.</p> <p>Service revenues from the new sales secured in the 4<sup>th</sup> quarter will be additive to our run rates for service revenues from both RIS and digital imaging sales from previous periods.</p> <p>North America</p> <p>The past year saw a number of significant changes in the group's US operations since the acquisition in January 2009. The group employs 12 people in the US to fulfil the sales marketing and professional services roles. The resultant sales saw a growth of 72.8% over the previous year, with some significant strategic sales that included placements at Brigham and Women's Hospital in Boston and University of Chicago. Visage 3D technology was featured as a technology breakthrough in several prominent journals. As such there is an expectation of further significant increases in revenues in this coming financial year.</p> <p>Europe</p> <p>Pro Medicus established a presence in Europe with the acquisition of Visage Imaging GmbH in late January 2009. The group has 33 employees in its Berlin office who undertake research and development of Visage Imaging products worldwide as well as sales, marketing and service/support functions for the group's European operations. Sales of the group's products in Europe both through direct sales and via OEM channels have met and in some areas exceeded budget expectations since the acquisition.</p> <p>Financials</p> <p>Full year revenue, which included a full twelve months of the Visage Imaging business rose from \$15.62 million to \$19.46 million, an increase of 24.6%.</p> <p>Net margin as defined by profit before tax to revenue from operating activities decreased from 48.5% to 32.3% in line with expectations as a result of the Visage Imaging acquisition.</p> <p>Profit after tax for the period was \$3.92 million a decrease of 21.9% from the previous year in what was a difficult year for the industry and the economy as a whole. However, the group continued to invest in research and development of its product and had high transactional operation costs, meant that full-year profit was lower than last year's.</p> <p>Shareholder Returns</p> <p>The Company is pleased to report a dividend return to shareholders of a total of 2.0 cents per share. This is made up of a final dividend of 2.0 cents.</p> <p>This level of dividend preserves balance sheet strength during the transition period of Integration of the overseas acquisitions.</p> <p>The directors are confident that the holdings of reserve cash after paying out the second half dividend is sufficient to underpin the development and expansion needs of the company as the business looks to increase its penetration of existing markets and new product development.</p>
<p><b>3.</b></p>	<p><b>Statement of Comprehensive Income</b></p> <p>Please refer to the Statement of Comprehensive Income in the attached Financial Statements.</p>
<p><b>4.</b></p>	<p><b>Statement of Financial Position</b></p> <p>Please refer to the Statement of Financial Position in the attached Financial Statements.</p>

5.	<p><b>Statement of cash flows</b></p> <p>Please refer to the Statement of cash flows in the attached Financial Statements.</p>																		
6.	<p><b>Details of Dividends</b></p> <table data-bbox="407 289 1403 625"> <thead> <tr> <th></th> <th style="text-align: right;">2010 \$'000</th> <th style="text-align: right;">2009 \$'000</th> </tr> </thead> <tbody> <tr> <td><b>Final Dividend</b></td> <td></td> <td></td> </tr> <tr> <td>A Final Dividend of 2.0 cents (2009: 2.0) per share fully franked will be paid on 1st November 2010.</td> <td style="text-align: right;">\$2,005.6</td> <td style="text-align: right;">\$2,005.6</td> </tr> <tr> <td><b>Current Year Interim</b></td> <td></td> <td></td> </tr> <tr> <td>No interim dividend was paid during 2009-10 (2009: 1.0 cents)</td> <td style="text-align: center;">-</td> <td style="text-align: right;">\$1,504.2</td> </tr> <tr> <td colspan="3">No foreign sourced dividend or distribution is included in either the interim or final dividends.</td> </tr> </tbody> </table>		2010 \$'000	2009 \$'000	<b>Final Dividend</b>			A Final Dividend of 2.0 cents (2009: 2.0) per share fully franked will be paid on 1st November 2010.	\$2,005.6	\$2,005.6	<b>Current Year Interim</b>			No interim dividend was paid during 2009-10 (2009: 1.0 cents)	-	\$1,504.2	No foreign sourced dividend or distribution is included in either the interim or final dividends.		
	2010 \$'000	2009 \$'000																	
<b>Final Dividend</b>																			
A Final Dividend of 2.0 cents (2009: 2.0) per share fully franked will be paid on 1st November 2010.	\$2,005.6	\$2,005.6																	
<b>Current Year Interim</b>																			
No interim dividend was paid during 2009-10 (2009: 1.0 cents)	-	\$1,504.2																	
No foreign sourced dividend or distribution is included in either the interim or final dividends.																			
7.	<p><b>Dividend or Distribution reinvestment plans</b></p> <p>There are no dividend or distribution reinvestment plans in operation.</p>																		
8.	<p><b>Statement of Retained Earnings</b></p> <p>Please refer to Statement of Changes in Equity in the attached Financial Statements.</p>																		
9.	<table data-bbox="407 926 1403 1045"> <thead> <tr> <th></th> <th style="text-align: right;">2010</th> <th style="text-align: right;">2009</th> </tr> </thead> <tbody> <tr> <td><b>Net Tangible Assets per security</b></td> <td></td> <td></td> </tr> <tr> <td>Net Tangible Assets per security</td> <td style="text-align: right;">\$0.07</td> <td style="text-align: right;">\$0.07</td> </tr> </tbody> </table>		2010	2009	<b>Net Tangible Assets per security</b>			Net Tangible Assets per security	\$0.07	\$0.07									
	2010	2009																	
<b>Net Tangible Assets per security</b>																			
Net Tangible Assets per security	\$0.07	\$0.07																	
10.	<p><b>Details of entities over which control has been gained or lost during the period</b></p> <p>There are no entities over which control has been gained or lost during the period</p>																		
11.	<p><b>Associates and joint venture entities</b></p> <p>There are no associates or joint venture entities</p>																		
12.	<p><b>Other significant information needed by an investor to make an informed assessment of the entity's financial performance and financial position.</b></p> <p>Please refer to section 2.6</p>																		
13.	<p><b>Foreign Entity accounting standards</b></p> <p>Australian Accounting Standards &amp; International Financial Reporting Standards</p>																		

14.	<p><b>Commentary on results for the period.</b> <b>The earnings per security and the nature of any dilution aspects.</b> Please refer to Note 8 of the attached Financial Statements.</p> <p><b>Returns to shareholders including distributions and buy backs.</b> Please refer to Note 9 of the attached Financial Statements.</p> <p><b>Significant features of operating performance.</b> Please refer to section 2.6.</p> <p><b>The results of segments that are significant to an understanding of the business.</b> Please refer to Note 5 of the attached Financial Statements.</p> <p><b>Discussion of trends in performance.</b> Please refer to section 2.6.</p>
15.	<p><b>Audit Statement</b></p> <p>This report is based on accounts to which one of the following applies. (Tick one)</p> <p><input checked="" type="checkbox"/> The +accounts have been audited.      <input type="checkbox"/> The +accounts have been subject to review.</p> <p><input type="checkbox"/> The +accounts are in the process of being audited.      <input type="checkbox"/> The +accounts have <i>not</i> yet been audited or reviewed.</p>

Sign here:

Date: 26 August 2010



Print name: David Chambers  
Chief Executive Officer